Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec;2(4):513-9.
doi: 10.2147/nedt.2006.2.4.513.

Effects of restless legs syndrome (RLS) on sleep

Richard K Bogan  1
Affiliations

Effects of restless legs syndrome (RLS) on sleep

Richard K Bogan. Neuropsychiatr Dis Treat. 2006 Dec.

Abstract

Restless legs syndrome (RLS) is a common neurological disorder characterized by an irresistible urge to move the legs, usually accompanied or caused by uncomfortable sensations in the legs. Symptoms are worse in the evening or at night than during the day and generally begin or worsen during periods of rest or inactivity. The chronic sleep disturbance often associated with RLS is likely due, at least in part, to the circadian nature of the symptoms. The relationship between disturbed sleep and reduced daytime functioning is well known and thus the accurate diagnosis and effective management of RLS is imperative.

Keywords: RLS; circadian; reduced daytime functioning; restless legs syndrome; sleep disturbance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adjusted mean change from baseline in domains of the Medical Outcomes Study Sleep Scale following treatment with ropinirole or placebo in patients with RLS, at week 12 last observation carried forward. Benefits are indicated by positive changes in sleep quantity and adequacy, and negative changes in sleep disturbance and somnolence. Pooled data are from three studies with similar design, TREAT RLS 1, 2 and US (Trenkwalder et al 2004; Walters et al 2004; Bogan et al 2006)a. Adjusted mean treatment difference: Sleep disturbance: −10.4; 95% CI: −13.4, −7.4; p<0.001 Daytime somnolence: −4.6; 95% CI: −7.0, −2.2; p<0.001 Sleep adequacy: 11.8; 95% CI: 8.3, 15.2; p<0.001 Sleep quantity: 0.5 hours; 95% CI: 0.3, 0.7; p<0.001 a In each individual study, adjusted mean treatment differences were in favor of ropinirole compared with placebo on all domains, except that statistical significance was not reached for daytime somnolence in the TREAT RLS US study. †p<0.001. Abbreviations: CI, confidence interval; MOS, Medical Outcomes Study Sleep Scale.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27:907–14. - PubMed
    1. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19. - PubMed
    1. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–13. - PubMed
    1. Allen RP, Earley CJ. Restless legs syndrome:a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128–47. - PubMed
    1. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact:REST general population study. Arch Intern Med. 2005;165:1286–92. - PubMed

LinkOut - more resources